![\"\"](\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/09\/20260922_Compass_Therapeutics_Therapeutic_Indications-768x432.png\")
<\/p>\n<\/p>\n
Company<\/strong><\/p>\n Compass Therapeutics<\/p>\n Event Type<\/strong><\/p>\n Regulatory Feedback<\/p>\n Modality<\/strong><\/p>\n Bispecific Antibody<\/p>\n Asset<\/strong><\/p>\n Tovecimig<\/p>\n Target<\/strong><\/p>\n DLL4 \/ VEGF-A<\/p>\n Disease Area<\/strong><\/p>\n Biliary Tract Cancer<\/p>\n Compass disclosed that FDA recommended a trial demonstrating overall survival benefit before a biologics license application for tovecimig in previously treated advanced biliary tract cancer. Compass disagrees that a new trial is warranted and plans further engagement while preparing a filing. The feedback materially weakens the near term regulatory path even though COMPANION 002 improved response and progression free survival.<\/p>\n In the randomized 168 participant study, tovecimig plus paclitaxel achieved a 17.1 percent response rate versus 5.3 percent and median progression free survival of 4.7 versus 2.6 months, with hazard ratio 0.44. Overall survival did not reach statistical significance. Fifty four percent of control patients crossed over, complicating interpretation.<\/p>\n Tovecimig is a bispecific antibody targeting DLL4 and VEGF A. Compass argues that crossover contributed to the survival result and that unmet need supports filing. FDA feedback is not a formal rejection, but the agency recommendation indicates that response and PFS may be insufficient for approval in the proposed setting.<\/p>\n Interpretation one is that crossover obscured a true survival benefit. Control patients crossing to active therapy lived longer than noncrossovers, which is directionally consistent. Against this, crossover adjustment relies on assumptions, and a trial designed with OS as a secondary endpoint did not produce a statistically significant result.<\/p>\n Interpretation two is that a new survival trial is necessary to establish benefit risk and distinguish the regimen from evolving standards. The countercase is feasibility: second line biliary tract cancer is heterogeneous, targetable subgroups and new therapies fragment enrollment, and withholding crossover may be difficult. Further FDA discussion could identify an alternative evidentiary path, but that outcome is uncertain.<\/p>\n Upgrade evidence includes written alignment on a filing or tractable confirmatory design, mature duration data and robust crossover adjusted analyses accepted by regulators. A requirement for a large prefiling OS trial, financing constraints or emerging superior comparators would further downgrade value.<\/p>\n Biliary tract cancers include cholangiocarcinoma and gallbladder cancer and have poor outcomes after first line therapy. DLL4 signaling contributes to tumor angiogenesis and vascular biology, while VEGF A drives blood vessel formation. Tovecimig combines both binding activities and was tested with paclitaxel in patients without an approved broadly effective second line option.<\/p>\n The signal is high importance and negative for timing and regulatory certainty. It does not negate the randomized response and PFS effects, and motive should not be inferred from agency language. The central issue is whether the existing package can support approval without direct survival evidence; current FDA feedback says it should not.<\/p>\n Signal Importance: 5 of 5. Signal Direction: negative for the proposed near term filing path. Confidence in Facts: high from the SEC filed disclosure. Confidence in Interpretation: moderate high, although further agency interaction could change the path.<\/p>\n","protected":false},"excerpt":{"rendered":" Compass disclosed that FDA recommended a trial demonstrating overall survival benefit before a biologics license application for tovecimig in previously treated advanced biliary tract cancer. Compass disagrees that a new trial is warranted and…<\/p>\n","protected":false},"author":1,"featured_media":3384,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,11,3],"tags":[120,119,839],"class_list":["post-3359","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-clinical","category-therapeutic-indication","tag-biliary-tract-cancer","tag-compass-therapeutics","tag-tovecimig"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3359","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3359"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3359\/revisions"}],"predecessor-version":[{"id":3390,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3359\/revisions\/3390"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3384"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3359"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3359"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3359"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Summary<\/h4>\n
Deep Analysis<\/h4>\n
Company and Product Background<\/h4>\n
Signal Extraction<\/h4>\n
\n
InSilens Take<\/h4>\n
Signal Assessment<\/h4>\n